Skip to main content
. 2018 Apr 26;62(5):e02419-17. doi: 10.1128/AAC.02419-17

FIG 1.

FIG 1

Drug delivery for CL. (A) Progression pathway during lead optimization of drugs as potential topical treatment for CL. (B) Histology of BALB/c mouse skin infected with L. major. The schematic (A) shows the route of the active drug through Leishmania-infected BALB/c mouse skin before reaching the Leishmania amastigotes situated in phagolysosome of dermal macrophages (B). PK, pharmacokinetics.